<DOC>
	<DOCNO>NCT01013675</DOCNO>
	<brief_summary>A control , double-blind study determine immunogenicity safety influenza cell derive vaccine elderly subject .</brief_summary>
	<brief_title>Immunogenicity Safety Cell-derived Influenza Vaccine Elderly</brief_title>
	<detailed_description>This current phase II study pursue objective similar ongoing adult phase II trial , expand elderly population 60 year age . The result randomize , double blind , egg derive influenza vaccine ( Influvac ) - control , parallel-trial , healthy elderly subject conduct two consecutive year multiple center Europe . At study initiation 600 subject randomly allocate receive cell-derived egg-derived influenza vaccine . At start second year subject randomly re-allocated follow stratification base upon initial drug allocate receive .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Willing able give inform consent able adhere protocol require study procedure . 2 . Men woman ( elderly ) 3 . Being good health judge medical history , physical examination clinical judgment investigator . Exclusion Criteria 1 . Known allergic constituent vaccine . 2 . A serious adverse reaction previous ( influenza ) vaccination . Presence significant condition may prohibit inclusion determine investigator . 3 . Having receive vaccination influenza lab confirm influenza within previous six month study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>influenza</keyword>
	<keyword>active-controlled</keyword>
	<keyword>Phase 2</keyword>
</DOC>